MARKET

UTHR

UTHR

Utd Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

94.83
+2.31
+2.50%
Closed 16:10 11/20 EST
OPEN
92.25
PREV CLOSE
92.52
HIGH
95.88
LOW
92.25
VOLUME
654.10K
TURNOVER
--
52 WEEK HIGH
128.94
52 WEEK LOW
74.31
MARKET CAP
4.16B
P/E (TTM)
-43.0166
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of UTHR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

UTHR News

  • Correvio Reports Third Quarter 2019 Financial Results
  • CNW Group.6d ago
  • Assessing MannKind's Q3 - What Investors Need To Know
  • Seeking Alpha - Article.11/10 19:03
  • Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat
  • Zacks.11/08 13:56
  • Only 1 Number Mattered in Arena Pharmaceuticals' Q3 Results -- and It Was Big
  • MotleyFool.com.11/08 11:00

More

Industry

Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
-0.14%

Hot Stocks

Name
Price
%Change

About UTHR

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.
More

Webull offers United Therapeutics Corporation (UTHR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.